|
Gene: ATP5B |
Gene summary for ATP5B |
Gene summary. |
Gene information | Species | Human | Gene symbol | ATP5B | Gene ID | 506 |
Gene name | ATP synthase F1 subunit beta | |
Gene Alias | ATP5B | |
Cytomap | 12q13.3 | |
Gene Type | protein-coding | GO ID | GO:0001503 | UniProtAcc | P06576 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
506 | ATP5B | GSM4909281 | Human | Breast | IDC | 1.81e-17 | -3.52e-01 | 0.21 |
506 | ATP5B | GSM4909282 | Human | Breast | IDC | 9.36e-17 | -3.52e-01 | -0.0288 |
506 | ATP5B | GSM4909285 | Human | Breast | IDC | 2.12e-16 | -3.52e-01 | 0.21 |
506 | ATP5B | GSM4909286 | Human | Breast | IDC | 9.36e-17 | -3.52e-01 | 0.1081 |
506 | ATP5B | GSM4909287 | Human | Breast | IDC | 1.12e-14 | -3.52e-01 | 0.2057 |
506 | ATP5B | GSM4909288 | Human | Breast | IDC | 1.24e-02 | -3.52e-01 | 0.0988 |
506 | ATP5B | GSM4909290 | Human | Breast | IDC | 3.25e-10 | -3.52e-01 | 0.2096 |
506 | ATP5B | GSM4909291 | Human | Breast | IDC | 4.44e-08 | -3.52e-01 | 0.1753 |
506 | ATP5B | GSM4909293 | Human | Breast | IDC | 9.36e-17 | -3.52e-01 | 0.1581 |
506 | ATP5B | GSM4909294 | Human | Breast | IDC | 1.81e-17 | -3.52e-01 | 0.2022 |
506 | ATP5B | GSM4909295 | Human | Breast | IDC | 4.00e-06 | -3.52e-01 | 0.0898 |
506 | ATP5B | GSM4909296 | Human | Breast | IDC | 4.80e-16 | -3.52e-01 | 0.1524 |
506 | ATP5B | GSM4909297 | Human | Breast | IDC | 2.86e-19 | -3.52e-01 | 0.1517 |
506 | ATP5B | GSM4909298 | Human | Breast | IDC | 7.93e-18 | -3.52e-01 | 0.1551 |
506 | ATP5B | GSM4909299 | Human | Breast | IDC | 4.12e-17 | -3.52e-01 | 0.035 |
506 | ATP5B | GSM4909300 | Human | Breast | IDC | 2.78e-05 | -3.52e-01 | 0.0334 |
506 | ATP5B | GSM4909301 | Human | Breast | IDC | 9.36e-17 | -3.52e-01 | 0.1577 |
506 | ATP5B | GSM4909302 | Human | Breast | IDC | 1.89e-14 | -3.52e-01 | 0.1545 |
506 | ATP5B | GSM4909303 | Human | Breast | IDC | 3.82e-03 | -3.52e-01 | 0.0438 |
506 | ATP5B | GSM4909304 | Human | Breast | IDC | 7.93e-18 | -3.52e-01 | 0.1636 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0019016 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0471418 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
hsa0541518 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0019017 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0471419 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
hsa0541519 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATP5B | SNV | Missense_Mutation | c.772N>G | p.Leu258Val | p.L258V | P06576 | protein_coding | deleterious_low_confidence(0.03) | benign(0.191) | TCGA-CD-A48C-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
ATP5B | SNV | Missense_Mutation | rs745377010 | c.1295A>G | p.Lys432Arg | p.K432R | P06576 | protein_coding | tolerated_low_confidence(0.07) | benign(0.053) | TCGA-CG-4301-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ATP5B | SNV | Missense_Mutation | rs766490903 | c.1385G>A | p.Arg462His | p.R462H | P06576 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.949) | TCGA-CG-4460-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | capecitabine | PD |
ATP5B | SNV | Missense_Mutation | c.1283T>C | p.Leu428Pro | p.L428P | P06576 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.627) | TCGA-HU-8602-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Chemotherapy | xeloda | CR | |
ATP5B | SNV | Missense_Mutation | c.929N>A | p.Arg310His | p.R310H | P06576 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.98) | TCGA-HU-A4G8-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | |
ATP5B | SNV | Missense_Mutation | c.929N>A | p.Arg310His | p.R310H | P06576 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.98) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |